ClinicalTrials.gg
CompletedNCT04426474Updated May 26, 2026Results posted

A Study of LY3502970 in Participants With Type 2 Diabetes

A Phase 1 interventional study of LY3502970 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
14th of 15
68 · median 546
Started
2020
the only one that year
Phase 1
2 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 1st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes mellitus (T2DM) for at least 6 months
  • Have a (HbA1c) value at screening of greater than or equal to (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening
  • Have a body weight of ≥45 kilograms (kg) and have a of 18.5 to 45 kilograms per square meter (kg/m²), inclusive
  • Have had a stable body weight for the 3 months prior to screening (less than [\<]5% body weight change)
  • Males and females (not considered woman of )

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus, latent diabetes in adults or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
  • Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), , cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure
  • Show evidence of , and/or positive hepatitis B surface antigen
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Any glucose-lowering medications other than metformin within 3 months prior to screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    LY3502970

    3, 6, 9, 12, 15, 21, 27, 36 and 45 milligrams (mg) LY3502970 administered orally.

    Drug: LY3502970

  • Placebo comparator
    Placebo

    Placebo administered orally.

    Drug: Placebo

Interventions

  • Administered orally.

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

    An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect and other situations based on medical judgement. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline through Follow-up (up to Day 105)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

    Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

    Time frame: Day 84: Predose 0.5, 1, 2, 4, 6, 8,12, 24, 48, 96 Hours Postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of LY3502970

    PK: area under the concentration versus time curve from time 0 to 24 hours \[AUC(0-24)\] of LY3502970

    Time frame: Day 84: Predose 0.5, 1, 2, 4, 6, 8,12, 24 Hours Postdose

  3. Pharmacodynamics (PD): Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG)

    Pharmacodynamics (PD): Change from Baseline to Week 12 in Fasting Plasma Glucose (FPG).

    Time frame: Baseline, Week 12

  4. PD: Change From Baseline to Week 12 in Fasting Insulin

    PD: Change From Baseline to Week 12 in Fasting Insulin.

    Time frame: Baseline, Week 12

07

Results

Posted May 26, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QD
Started171491099
Received at least one dose of study drug171491099
Completed1169989
Not completed680110
Withdrew: Adverse event450110
Withdrew: Withdrawal by subject120000
Withdrew: Lost to follow-up110000

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect and other situations based on medical judgement. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

Time frame:
Baseline through Follow-up (up to Day 105)
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
ParticipantsPlacebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QD
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug100000
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

Time frame:
Day 84: Predose 0.5, 1, 2, 4, 6, 8,12, 24, 48, 96 Hours Postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970
nanograms/milliliter (ng/mL)3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QD
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970101 ± 2857.9 ± 7897.9 ± 30191 ± 59218 ± 40
SecondaryPK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of LY3502970

PK: area under the concentration versus time curve from time 0 to 24 hours \[AUC(0-24)\] of LY3502970

Time frame:
Day 84: Predose 0.5, 1, 2, 4, 6, 8,12, 24 Hours Postdose
Reported as:
Geometric least squares mean · nanograms hour per milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of LY3502970
nanograms hour per milliliter (ng*h/mL)3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QD
PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of LY35029701480 ± 23850 ± 731600 ± 293120 ± 533520 ± 29
SecondaryPharmacodynamics (PD): Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG)

Pharmacodynamics (PD): Change from Baseline to Week 12 in Fasting Plasma Glucose (FPG).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · millimoles per litre (mmol/L)
Pharmacodynamics (PD): Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG)
millimoles per litre (mmol/L)Placebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QD
Pharmacodynamics (PD): Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG)-1.14 ± 0.47-2.02 ± 0.60-3.00 ± 0.54-2.85 ± 0.55-2.42 ± 0.57-2.29 ± 0.55
Statistical analysis
  • Placebo QD vs 3/6/12/21 mg LY3502970 QD · Least squares mean difference: -0.87 · 90% CI -2.15 to 0.40
  • Placebo QD vs 3/6/9 mg LY3502970 QD · Least squares mean difference: -1.86 · 90% CI -3.07 to -0.65
  • Placebo QD vs 3/6/12/15 mg LY3502970 QD · Least Squares Mean Difference · Least squares mean difference: -1.70 · 90% CI -2.91 to -0.50
  • Placebo QD vs 3/6/12/21/27 mg LY3502970 QD · Least squares mean difference: -1.28 · 90% CI -2.52 to -0.03
  • Placebo QD vs 3/6/9/21/36/45 mg LY3502970 QD · Least squares mean difference: -1.14 · 90% CI -2.35 to 0.07
SecondaryPD: Change From Baseline to Week 12 in Fasting Insulin

PD: Change From Baseline to Week 12 in Fasting Insulin.

Time frame:
Baseline, Week 12
Reported as:
Mean · picomoles/litre (pmol/L)
PD: Change From Baseline to Week 12 in Fasting Insulin
picomoles/litre (pmol/L)Placebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QD
PD: Change From Baseline to Week 12 in Fasting Insulin-9.71 ± 11.14-12.20 ± 13.13-5.46 ± 14.4815.16 ± 17.977.30 ± 17.09-1.32 ± 15.63
Statistical analysis
  • Placebo QD vs 3/6/12/21 mg LY3502970 QD · Difference in estimated mean change: -2.50 · 90% CI -30.82 to 25.83
  • Placebo QD vs 3/6/9 mg LY3502970 QD · Difference in estimated mean change: 4.24 · 90% CI -25.81 to 34.30
  • Placebo QD vs 3/6/12/15 mg LY3502970 QD · [difference in estimated mean change: 24.87 · 90% CI -9.91 to 59.65
  • Placebo QD vs 3/6/12/21/27 mg LY3502970 QD · [difference in estimated mean change: 17.01 · 90% CI -16.55 to 50.57
  • Placebo QD vs 3/6/9/21/36/45 mg LY3502970 QD · [difference in estimated mean change: 8.38 · 90% CI -23.19 to 39.95

Adverse events

Collected over Baseline through Follow-up (up to Day 105). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QD0/17 (0%)1/17 (5.9%)7/17 (41.2%)
3/6/12/21 mg LY3502970 QD0/14 (0%)0/14 (0%)10/14 (71.4%)
3/6/9 mg LY3502970 QD0/9 (0%)0/9 (0%)8/9 (88.9%)
3/6/12/15 mg LY3502970 QD0/10 (0%)0/10 (0%)9/10 (90%)
3/6/12/21/27 mg LY3502970 QD0/9 (0%)0/9 (0%)8/9 (88.9%)
3/6/9/21/36/45 mg LY3502970 QD0/9 (0%)0/9 (0%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventPlacebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QD
Hand fractureInjury, poisoning and procedural complications1/170/140/90/100/90/9
Skin lacerationInjury, poisoning and procedural complications1/170/140/90/100/90/9
Lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/170/140/90/100/90/9
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPlacebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QD
NauseaGastrointestinal disorders1/176/144/95/103/97/9
Decreased appetiteMetabolism and nutrition disorders2/174/144/94/105/96/9
VomitingGastrointestinal disorders0/172/145/95/105/95/9
ConstipationGastrointestinal disorders0/170/143/90/101/90/9
DyspepsiaGastrointestinal disorders1/170/142/91/102/93/9
EructationGastrointestinal disorders0/170/141/93/102/92/9
HeadacheNervous system disorders1/170/142/93/101/92/9
Abdominal distensionGastrointestinal disorders0/171/140/91/102/92/9
DiarrhoeaGastrointestinal disorders3/171/140/91/102/91/9
Early satietyGeneral disorders0/170/141/92/101/92/9

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QDTotal
Mean56.0 ± 6.055.3 ± 8.057.7 ± 6.459.6 ± 4.658.8 ± 4.662.8 ± 4.457.9 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QDTotal
Female74532526
Male1010477442
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QDTotal
Hispanic or Latino78433530
Not Hispanic or Latino106576438
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QDTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American2402019
White1410989858
More than one race1000001
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Placebo QD3/6/12/21 mg LY3502970 QD3/6/9 mg LY3502970 QD3/6/12/15 mg LY3502970 QD3/6/12/21/27 mg LY3502970 QD3/6/9/21/36/45 mg LY3502970 QDTotal
United States1014443540
Germany70566428
08

Study locations

6 sites
  • Clinical Pharmacology of Miami
    Hialeah, Florida 33014, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Midwest Clinical Research Unit
    Dayton, Ohio 45417, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78229, United States
  • Profil Institut für Stoffwechselforschung
    Neuss, North Rhine-Westphalia 41460, Germany
  • Profil Mainz
    Mainz, 55116, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jul 2021, 9 months.

Results were first posted in May 2026, 4 years 10 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2020
First posted
Jun 11, 2020
StartActual
Oct 8, 2020
Primary completionActual
Jul 12, 2021
CompletionActual
Jul 12, 2021
Results first posted
May 26, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04426474
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Oct 8, 2020
Primary completion
Jul 12, 2021
Completion
Jul 12, 2021
Results posted
May 26, 2026
Last update
May 26, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion